.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,872,407

« Back to Dashboard

Details for Patent: 6,872,407

Title: Extended release formulations of erythromycin derivatives
Abstract:Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower C.sub.max in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
Inventor(s): Notario; Gerard F. (Chicago, IL), Palmer; Robert N. (Gurnee, IL), Hom; Richard C. (Wilmette, IL), Zhang; Jie (Basking Ridge, NJ), Devcich; Karen J. (Grayslake, IL), Semla; Susan J. (Evanston, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Filing Date:Nov 22, 2002
Application Number:10/302,166
Claims:1. A pharmaceutical composition for extended release of clarithromycin in the gastrointestinal tract, to be administered orally, comprising clarithromycin, which, when administered once a day, induces a statistically significantly lower degree of fluctuation value for the clarithromycin concentration in plasma than an equal dosing of the immediate release composition of clarithromycin administered twice a day, while maintaining exposure (AUC.sub.0-24) substantially equivalent to the immediate release composition of clarithromycin, wherein the composition further induces a statistically significant lower degree of fluctuation value in plasma than that of the controlled release formulation containing clarithromycin, a water soluble alginate salt, a complex salt of alginic acid, and an organic carboxylic acid, and, which releases clarithromycin so that after a regimen of a single 1000 mg dose on day 1 and a multiple dose regimen of 1000 mg on days 3, 4 and 5, the C.sub.max is about 2.45 .mu.g/ml, the C.sub.min is about 0.70 .mu.g/ml, the T.sub.max is about 8.6 hours, the AUC.sub.0-24 is about 39.6 .mu.g.multidot.h/mL, and the fluctuation index is about 1.11.

2. The pharmaceutical composition of claim 1, wherein the composition when administered to a patient has improved taste perversion compared to an immediate release formulation containing clarithromycin.

3. The pharmaceutical composition of claim 1, wherein the composition when administered to a patient has reduced severity of gastrointestinal adverse side effects.

4. The pharmaceutical composition of claim 1, further providing a 3-4 fold reduction in incidence rates for taste perversion as compared to the immediate release formulation containing clarithromycin when administered to a group of patients.

5. The pharmaceutical composition of claim 1, further a pharmaceutically acceptable polymer.

6. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable polymer selected from the group consisting of polyvinylpyrrolidine, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, vinyl acetate/crotonic acid copolymers, methacrylic acid copolymers, maleic anhydride/methyl vinyl ether copolymers and mixtures thereof.

7. The pharmaceutical composition of claim 6, comprising 10 to 30% by weight hydroxypropylmethyl cellulose and 45-60% by weight clarithromycin.

8. A pharmaceutical composition for extended release of clarithromycin in the gastrointestinal tract, to be administered orally, comprising clarithromycin, which, when administered once a day, induces a statistically significantly lower degree of fluctuation value for the clarithromycin concentration in plasma than an equal dosing of the immediate release composition of clarithromycin administered twice a day, while maintaining exposure (AUC.sub.0-24) substantially equivalent to the immediate release composition of clarithromycin, wherein the composition further induces a statistically significant lower degree of fluctuation value in plasma than that of the controlled release formulation containing clarithromycin, a water soluble alginate salt, a complex salt of alginic acid, and an organic carboxylic acid, and, which releases clarithromycin so that after a regimen of a single 1000 mg dose on day 1 and a multiple dose regimen of 1000 mg on days 3, 4 and 5, the C.sub.max is about 2.66 .mu.g/ml, the C.sub.min is about 0.67 .mu.g/ml, the T.sub.max is about 6.9 hours, the AUC.sub.0-24 is about 40.2 .mu.g.multidot.h/mL, and the fluctuation index is about 1.24.

9. The pharmaceutical composition of claim 8, wherein the composition when administered to a patient has improved taste perversion compared to an immediate release formulation containing clarithromycin.

10. The pharmaceutical composition of claim 8, wherein the composition when administered to a patient has reduced severity of gastrointestinal adverse side effects.

11. The pharmaceutical composition of claim 8, further providing a 3-4 fold reduction in incidence rates for taste perversion as compared to the immediate release formulation containing clarithromycin when administered to a group of patients.

12. The pharmaceutical composition of claim 8, further comprising a pharmaceutically acceptable polymer.

13. The pharmaceutical composition of claim 8, further comprising a pharmaceutically acceptable polymer selected from the group consisting of polyvinylpyrrolidine, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, vinyl acetate/crotonic acid copolymers, methacrylic acid copolymers, maleic anhydride/methyl vinyl ether copolymers and mixtures thereof.

14. The pharmaceutical composition of claim 13, comprising 10 to 30% by weight hydroxypropylmethyl cellulose and 45-60% a by weight clarithromycin.

15. The pharmaceutical composition of claim 1, wherein, the C.sub.max is 2.45.+-.0.69 .mu.g/ml, the C.sub.min is 0.70.+-.0.37 .mu.g/ml, the T.sub.max is 8.6.+-.4.4 hours, the AUC.sub.0-24 is 39.6.+-.12.8 .mu.g.multidot.h/mL, and the fluctuation index is 1.11.+-.0.31.

16. The pharmaceutical composition of claim 8, wherein the C.sub.max is 2.66.+-.0.87 .mu.g/ml, the C.sub.min is 0.67.+-.0.39 .mu.g/ml, the T.sub.max is 6.9.+-.3.3 hours, the AUC.sub.0-24 is 40.2.+-.13.8 .mu.g.multidot.h/mL, and the fluctuation index is 1.24.+-.0.37.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc